Avutometinib + Defactinib for Endometrial Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you must stop all current medications, but you cannot take certain medications that interact with the study drugs. Specifically, you must avoid strong CYP3A4, CYP2C9, and P-glycoprotein inhibitors or inducers, as well as strong breast cancer resistance protein inhibitors or inducers, within 14 days before starting the trial and during the trial. If you are on warfarin, you will need to switch to another anticoagulant.
Will I have to stop taking my current medications?
The trial requires stopping certain medications that interact with the study drugs, such as strong CYP3A4, CYP2C9, and P-glycoprotein inhibitors or inducers, 14 days before starting the trial. If you are on warfarin, you may need to switch to another blood thinner.
What data supports the idea that Avutometinib + Defactinib for Endometrial Cancer is an effective drug?
The available research does not provide specific data on the effectiveness of Avutometinib + Defactinib for Endometrial Cancer. The studies mentioned focus on other drug combinations for different types of cancer, such as melanoma and colorectal cancer, and do not include information on Avutometinib + Defactinib for Endometrial Cancer. Therefore, there is no direct evidence from the provided information to support the effectiveness of this drug combination for Endometrial Cancer.12345
What safety data is available for Avutometinib and Defactinib in endometrial cancer treatment?
The provided research does not contain specific safety data for Avutometinib (VS-6766) and Defactinib (VS-6063) in the treatment of endometrial cancer. The studies focus on other BRAF and MEK inhibitors like vemurafenib, dabrafenib, trametinib, and selumetinib in melanoma and lung cancer, which have different safety profiles. Therefore, specific safety data for Avutometinib and Defactinib would need to be sourced from clinical trials or studies directly involving these drugs.678910
Is the drug Avutometinib (VS-6766) and Defactinib a promising treatment for endometrial cancer?
What makes the drug Avutometinib + Defactinib unique for endometrial cancer?
Avutometinib and Defactinib work together to target specific pathways in cancer cells, potentially offering a new approach for treating endometrial cancer by inhibiting both Raf/MEK and FAK pathways, which are involved in cancer cell growth and survival. This combination is being explored for its potential to provide a more effective treatment option compared to standard therapies.311121314
What is the purpose of this trial?
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Research Team
Rachel Grisham, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for women over 18 with advanced or recurrent mesonephric gynecologic cancer. They must have good kidney and liver function, no severe heart issues, and cannot be pregnant or breastfeeding. Prior treatment with certain inhibitors or a history of rhabdomyolysis excludes participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Avutometinib (VS-6766) and Defactinib for 3 weeks followed by a 1 week rest period in each 4-week cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Avutometinib (VS-6766)
- Defactinib
Avutometinib (VS-6766) is already approved in United States for the following indications:
- Recurrent low-grade serous ovarian cancer (Breakthrough Therapy Designation)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Verastem, Inc.
Industry Sponsor